Clinical trials: Cognitive Disorder Patients and Cognitive Assessment
Cognitive Impairment, Long COVID
Addressing Cognitive Fog in Long-COVID-19 Patients
This study will assess two options to help patients better manage the cognitive fog and emotional distress that may be associated with having Long-COVID.
- Trial name
- NCT05597722
- Testing
- Digital cognitive behavioral intervention-RxWell, Amphetamine-Dextroamphetamine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Eva Szigethy
Rheumatoid Arthritis, Cardiovascular Diseases
Cardiovascular Risk Assessment for Patients With Rheumatoid Arthritis Arthritis:
One of the greatest success stories in rheumatology - the achievement of rheumatoid arthritis (RA) remission - is tempered by the fact that individuals with RA are dramatically under evaluated and under treated to reduce the risk…
- Conditions
- Rheumatoid Arthritis, Cardiovascular Diseases, Hyperlipidemias
- Trial name
- CARE RA (NCT04488497)
- Testing
- Cardiovascular Risk Assessment for Patients with Rheumatoid Arthritis, Standard of care
- Where
- United States
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Mild Cognitive Impairment, Dementia
A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment
The purpose of this study is to determine whether treatment with the investigational drug ladostigil will delay the onset of Alzheimer's disease(AD) in patients with Mild Cognitive Impairment (MCI).
- Trial name
- NCT01429623
- Testing
- ladostigil hemitartrate
- Where
- 12 sites in Austria, Germany and 1 more
- Volunteers
- 210 people
- Sponsor
- Avraham Pharmaceuticals Ltd
Anxiety Disorder, Cognitive/Functional Effects
Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer
RATIONALE: Participating in a physical activity program designed to increase free time physical activity and receiving written health education materials may influence the chance of cancer recurring as well as impact on physical…
- Conditions
- Anxiety Disorder, Cognitive/Functional Effects, Colorectal Cancer, Depression
- Trial name
- CHALLENGE (NCT00819208)
- Testing
- exercise intervention, counseling intervention, educational intervention
- Where
- 47 sites in United States, Australia and 4 more
- Volunteers
- 889 people
- Sponsor
- Canadian Cancer Trials Group
Parkinson Disease, Healthy Participants
A Study of TAK-071 in People With Parkinson Disease
It is hoped that TAK-071 will help people with Parkinson's disease to walk with better balance. The main aim of the study is to check if there is a difference in how participants walk after treatment with TAK-071.
- Trial name
- NCT04334317
- Testing
- TAK-071
- Where
- 21 sites in United States
- Volunteers
- 64 people
- Sponsor
- Takeda
Stroke, Brain Infarction
Intervention Effectiveness Towards Improving Physical and Mental Health for Post-stroke Patients.
This was a multi-intervention randomized controlled trial that aimed to develop a management pattern for stroke survivors. The program consisted of monitoring the recovery process, early detecting the physical and mental…
- Conditions
- Stroke, Brain Infarction, Brain Ischemia, Cerebral Infarction
- Trial name
- NCT04941482
- Testing
- Periodic health check program for post-stroke, Guiding the appropriate rehabilitation exercises, Motivational Interviewing
- Where
- Vietnam
- Volunteers
- 92 people
- Sponsor
- Hanoi Medical University
Cognitive Impairment, End Stage Renal Disease
A Study to Assess the Tolerability and Efficacy of AKST1210 in Patients on Hemodialysis With Cognitive Impairment
This study will evaluate the tolerability, feasibility, and efficacy of the AKST1210 column in subjects with end-stage renal disease with cognitive impairment (ESRD-CI) undergoing hemodialysis 3 times per week.
- Trial name
- NCT04527328
- Testing
- AKST1210, Hemodialysis
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Alkahest, Inc.
Alzheimer's Disease
Resveratrol for Alzheimer's Disease
Resveratrol is derived from plants and is found in highest levels in red wine and the skin of red grapes. A recent study reported that monthly and weekly consumption of red wine is associated with a lower risk of dementia.
- Trial name
- NCT01504854
- Testing
- Resveratrol
- Where
- 26 sites in United States
- Volunteers
- 119 people
- Sponsor
- Alzheimer's Disease Cooperative Study (ADCS)
Mild Cognitive Impairment, Alzheimer Disease
Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease
The purpose of this platform study was to evaluate the effect of anti-inflammatory agents on cognition in early Alzheimer's disease.
- Trial name
- NCT04795466
- Testing
- Canakinumab
- Where
- 10 sites in United States, Finland and 2 more
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer Disease
A Study of LY3002813 in Participants With Alzheimer's Disease
The study will evaluate the safety of LY3002813 by looking at adverse events. The study will also look at the effect the body has on LY3002813.
- Trial name
- NCT01837641
- Testing
- LY3002813-IV, LY3002813-SC
- Where
- 6 sites in United States, Japan
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Meningioma
Magnesium and Intraoperative Blood Loss in Meningioma Surgery
Meningioma is the most common central nervous system tumor and craniotomy with tumor removal was associated with moderate blood loss and blood transfusion.
- Trial name
- NCT03558516
- Testing
- Magnesium group, Normal saline group
- Where
- Thailand
- Volunteers
- 80 people
- Sponsor
- Mahidol University
Post Operative Pain
Parent Nurse Controlled Analgesic in Pediatric Patients With Developmental Delay
The purpose of this study is to compare, the safety, efficacy and level of parent and nurse satisfaction with three methods of opioid administration post-operatively in children (4-18 years of age) with developmental delay.
- Trial name
- PNCA (NCT00743730)
- Testing
- Pain and standard side effect management for PNCA with basal method., Pain and standard side effect management with PNCA without basal, Pain and standard side effect management with IV on an as needed basis method.
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Medical College of Wisconsin
Alzheimer Disease
A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease
The study involves repeated doses of LY3303560 given by infusion for 49 weeks. The study will examine how safe repeated doses of LY3303560 are, whether they cause side effects in participants with mild cognitive impairment or…
- Trial name
- NCT03019536
- Testing
- LY3303560 - IV, Florbetapir F 18, Flortaucipir F18
- Where
- 11 sites in United States, Japan and 1 more
- Volunteers
- 22 people
- Sponsor
- Eli Lilly and Company
Chronic Cerebral Ischemia
Safety and Efficacy of Sequential Therapy With Mexidol® in Patients With Chronic Cerebral Ischemia
The purpose of this study is to evaluate safety and efficacy of sequential treatment with Mexidol® in patients with chronic cerebral ischemia (CCI).
- Trial name
- MEMO (NCT06834490)
- Testing
- Mexidol
- Where
- 14 sites in Russia, Uzbekistan
- Volunteers
- 318 people
- Sponsor
- Pharmasoft
Multiple Sclerosis, Relapsing Multiple Sclerosis
Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients
To assess safety and tolerability of patients converting from approved Relapsing Multiple Sclerosis (RMS) Disease Modifying Therapies (DMTs) to siponimod.
- Conditions
- Multiple Sclerosis, Relapsing Multiple Sclerosis, Advancing Multiple Sclerosis
- Trial name
- EXCHANGE (NCT03623243)
- Testing
- Siponimod
- Where
- 55 sites in United States, Puerto Rico
- Volunteers
- 185 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer's Disease, Dementia
Safety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease
For many, Alzheimer's disease is the number one medical issue facing our aging society. It is a late onset neurodegenerative disease, frequently under diagnosed, that impairs memory and cognitive performance.
- Conditions
- Alzheimer's Disease, Dementia, Memory Loss, Cognitive Impairment
- Trial name
- NCT01354691
- Testing
- ladostigil hemitartrate
- Where
- 19 sites in Austria, Croatia and 3 more
- Volunteers
- 200 people
- Sponsor
- Avraham Pharmaceuticals Ltd
Alzheimer's Disease
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
The purpose of this Phase 1/Phase 2 study is to evaluate how the body handles the drug and the drug's effect on the body of participants with mild cognitive impairment (MCI) due to Alzheimer's Disease (AD) or mild AD and who test…
- Trial name
- NCT01561430
- Testing
- LY2886721
- Where
- 34 sites in United States, Italy and 3 more
- Volunteers
- 70 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Cognitive Behavioral Therapy for African Americans With Uncontrolled Type-2 Diabetes
The main purpose of the study is to assess the feasibility and acceptability of a Culturally-Tailored Cognitive Behavior intervention (CT-CB) for African American patients with uncontrolled Type 2 diabetes.
- Trial name
- NCT03562767
- Testing
- Group-based Cognitive Behavioral Intervention, Web-based Cognitive Behavioral Intervention, Usual Care
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Emory University
Schizophrenia
Efficacy of Cognitive Remediation in Patients With Schizophrenia or Schizoaffective Disorder Stabilized on Lurasidone
The investigators hypothesize that cognitive remediation will be superior to the active control group on the change from baseline to study end point of cognitive remediation phase on both co-primary outcome measures (standardized…
- Trial name
- NCT01173874
- Testing
- Cognitive Remediation
- Where
- 16 sites in United States
- Volunteers
- 120 people
- Sponsor
- New York State Psychiatric Institute
Alzheimer's Disease
A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)
The purpose of this study is to evaluate the safety and tolerability of the study drug, LY3303560. Side effects and laboratory results will be monitored.
- Trial name
- NCT02754830
- Testing
- LY3303560 - IV, Saline Solution - IV, LY3303560 - SC
- Where
- 2 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company